About Impax Laboratories (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:IPXL
- CUSIP: 45256B10
- Web: www.impaxlabs.com
- Market Cap: $1.53 billion
- Outstanding Shares: 71,826,000
- 50 Day Moving Avg: $21.43
- 200 Day Moving Avg: $17.41
- 52 Week Range: $7.75 - $25.70
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 20.24
- P/E Growth: 2.31
- Annual Revenue: $812.82 million
- Price / Sales: 1.88
- Book Value: $7.32 per share
- Price / Book: 2.90
- EBITDA: $144.42 million
- Net Margins: -71.08%
- Return on Equity: 9.05%
- Return on Assets: 3.20%
- Debt-to-Equity Ratio: 1.46%
- Current Ratio: 1.75%
- Quick Ratio: 1.19%
- Average Volume: 1.89 million shs.
- Beta: 1.13
- Short Ratio: 4.78
Frequently Asked Questions for Impax Laboratories (NASDAQ:IPXL)
What is Impax Laboratories' stock symbol?
Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."
How were Impax Laboratories' earnings last quarter?
Impax Laboratories, Inc. (NASDAQ:IPXL) released its quarterly earnings data on Wednesday, August, 9th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.14 by $0.04. The business earned $202.08 million during the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The business's revenue was up 17.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.21 EPS. View Impax Laboratories' Earnings History.
When will Impax Laboratories make its next earnings announcement?
What guidance has Impax Laboratories issued on next quarter's earnings?
Impax Laboratories issued an update on its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share (EPS) guidance of $0.55-0.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.66.
Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2017?
15 equities research analysts have issued 1 year price objectives for Impax Laboratories' shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Impax Laboratories' share price to reach $19.67 in the next twelve months. View Analyst Ratings for Impax Laboratories.
What are analysts saying about Impax Laboratories stock?
Here are some recent quotes from research analysts about Impax Laboratories stock:
- 1. According to Zacks Investment Research, "Impax’s Generics segment is facing competitive and pricing pressure, which is expected to persist through 2017. However, epinephrine auto-injector sales have picked up The company is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. Moreover, the company’s manufacturing facilities have been hampered by quality control issues since 2011, which delayed Rytary’s approval. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. However, the generics market is highly crowded and Impax faces stiff competition from other major companies. Impax’s shares have outperformed the industry so far this year. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters." (10/20/2017)
- 2. Cantor Fitzgerald analysts commented, "We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with IPXL in attendance." (9/25/2017)
- 3. Guggenheim analysts commented, "Impax (IPXL, BUY, $12.70) named Paul Bisaro as its new, full-time CEO earlier today, which increases our confidence that there could be upside to consensus expectations in '17+. Bisaro has 25 years of generic and branded pharma experience, with an impressive track record of execution and transformation at companies like Allergan (AGN, NEUTRAL, $237.33) and its predecessors and Barr Pharmaceuticals (acquired by TEVA [BUY, $32.76] in 2010). Bisaro is also on the Board of Directors of AGN and Zoetis (ZTS, BUY, $53.85)." (3/27/2017)
- 4. Royal Bank Of Canada analysts commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS given, as expected). We continue to see a number of generic headwinds that will linger as IPXL pursues a leadership change and what we see as needed review of strategic positioning. We lower EPS and target to reflect continued challenges. Remain Sector Perform." (3/2/2017)
Who are some of Impax Laboratories' key competitors?
Some companies that are related to Impax Laboratories include BTG plc (BTG), Hikma Pharmaceuticals Plc (HIK), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Emergent Biosolutions (EBS), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Akcea Therapeutics (AKCA), Lannett Co (LCI), Amphastar Pharmaceuticals (AMPH), SciClone Pharmaceuticals (SCLN), AMAG Pharmaceuticals (AMAG), Corium International (CORI), Collegium Pharmaceutical (COLL) and Teligent (TLGT).
Who are Impax Laboratories' key executives?
Impax Laboratories' management team includes the folowing people:
- Robert L. Burr, Independent Chairman of the Board
- Paul M. Bisaro, President, Chief Executive Officer, Director
- Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance
- Douglas S. Boothe, President - Generics Division
- Michael J. Nestor, President - Impax Specialty Pharmaceutical Division
- Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary
- Jeffrey D. Nornhold, Senior Vice President - Technical Operations
- J. Kevin Buchi, Director
- Janet S. Vergis, Director
- Leslie Z. Benet Ph.D., Independent Director
Who owns Impax Laboratories stock?
Impax Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) COMPANY ., LTD.
(5.19%) and Fisher Asset Management LLC (2.08%). Company insiders that own Impax Laboratories stock include Leslie Z Benet and Michael Nestor. View Institutional Ownership Trends for Impax Laboratories.
Who bought Impax Laboratories stock? Who is buying Impax Laboratories stock?
How do I buy Impax Laboratories stock?
Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Impax Laboratories' stock price today?
MarketBeat Community Rating for Impax Laboratories (NASDAQ IPXL)MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Impax Laboratories stock can currently be purchased for approximately $21.25.
Consensus Ratings for Impax Laboratories (NASDAQ:IPXL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 9 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.27)|
|Consensus Price Target: ||$19.67 (7.45% downside)|Consensus Price Target History for Impax Laboratories (NASDAQ:IPXL)
Analysts' Ratings History for Impax Laboratories (NASDAQ:IPXL)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/17/2017||Royal Bank Of Canada||Set Price Target||Hold||$17.00||N/A|
|10/17/2017||Canaccord Genuity||Set Price Target||Hold||$19.00||N/A|
|10/17/2017||Cantor Fitzgerald||Set Price Target||Buy||$25.00||N/A|
|9/28/2017||Goldman Sachs Group, Inc. (The)||Initiated Coverage||Neutral||$20.00||High|
|9/23/2017||BTIG Research||Reiterated Rating||Buy||$20.00 -> $27.00||Low|
|9/19/2017||Deutsche Bank AG||Reiterated Rating||Buy||$23.00||Low|
|9/19/2017||Citigroup Inc.||Boost Price Target||Buy||$23.00||Low|
|9/17/2017||Piper Jaffray Companies||Reiterated Rating||Hold||$17.00||Low|
|8/9/2017||Cowen and Company||Set Price Target||Hold||$12.00 -> $20.00||High|
|6/23/2017||BMO Capital Markets||Reiterated Rating||Hold||$16.00||Low|
|6/12/2017||Janney Montgomery Scott||Reiterated Rating||Neutral||$21.00||High|
|3/8/2017||Susquehanna Bancshares Inc||Downgrade||Positive -> Neutral||$18.00 -> $10.00||Low|
|11/14/2016||WallachBeth Capital||Downgrade||Buy -> Hold||$30.00 -> $18.00||N/A|
|11/7/2016||Bank of America Corporation||Downgrade||Neutral -> Underperform||$19.00||N/A|
|8/15/2016||Northland Securities||Upgrade||Market Perform -> Outperform||$30.00||N/A|
|8/10/2016||Leerink Swann||Lower Price Target||Market Perform||$33.00 -> $24.00||N/A|
|6/1/2016||J P Morgan Chase & Co||Initiated Coverage||Neutral||$47.00||N/A|
|2/17/2016||Raymond James Financial, Inc.||Upgrade||Underperform -> Market Perform||N/A|
Earnings History for Impax Laboratories (NASDAQ:IPXL)Earnings History by Quarter for Impax Laboratories (NASDAQ IPXL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||$0.14||$0.18||$195.62 million||$202.08 million||View||Listen|
|5/10/2017||Q1 2017||$0.12||$0.11||$193.17 million||$184.40 million||View||N/A|
|3/1/2017||Q416||$0.16||$0.16||$219.54 million||$198.40 million||View||Listen|
|11/9/2016||Q316||$0.40||$0.37||$234.87 million||$228.00 million||View||Listen|
|8/9/2016||Q216||$0.32||$0.21||$223.67 million||$173.00 million||View||N/A|
|5/10/2016||Q116||$0.39||$0.43||$241.84 million||$226.00 million||View||Listen|
|2/22/2016||Q415||$0.44||$0.62||$223.23 million||$282.10 million||View||Listen|
|11/9/2015||Q315||$0.39||$0.40||$214.69 million||$221.10 million||View||N/A|
|8/10/2015||Q215||$0.35||$0.34||$200.68 million||$214.20 million||View||Listen|
|5/11/2015||Q115||$0.18||$0.09||$146.00 million||$143.10 million||View||Listen|
|2/24/2015||Q414||$0.11||$0.16||$125.50 million||$131.20 million||View||N/A|
|11/4/2014||Q314||$0.31||$0.33||$148.36 million||$145.63 million||View||N/A|
|8/6/2014||Q214||$0.39||$0.60||$155.97 million||$188.10 million||View||N/A|
|5/1/2014||Q114||$0.13||$0.24||$97.80 million||$118.70 million||View||N/A|
|2/20/2014||Q413||$0.03||($0.14)||$119.01 million||$100.74 million||View||N/A|
|11/4/2013||Q313||($0.08)||$0.25||$111.83 million||$115.75 million||View||N/A|
|8/8/2013||Q2 2013||$0.04||$0.08||$120.75 million||$129.63 million||View||N/A|
|5/1/2013||Q1 2013||$0.21||$0.37||$129.12 million||$148.50 million||View||N/A|
|2/25/2013||Q4 2012||$0.19||$0.30||$127.03 million||$141.10 million||View||N/A|
|10/30/2012||Q312||$0.49||$0.48||$160.76 million||$145.60 million||View||N/A|
Earnings Estimates for Impax Laboratories (NASDAQ:IPXL)
2017 EPS Consensus Estimate: $0.87
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Impax Laboratories (NASDAQ:IPXL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Impax Laboratories (NASDAQ:IPXL)
Insider Ownership Percentage: 3.20%Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Institutional Ownership Percentage: 86.26%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/31/2017||Michael Nestor||Insider||Sell||1,130||$15.00||$16,950.00|| |
|5/17/2017||Michael Nestor||Insider||Sell||857||$16.48||$14,123.36|| |
|5/12/2017||Michael Nestor||Insider||Sell||700||$17.11||$11,977.00|| |
|8/15/2016||Leslie Z Benet||Director||Sell||10,092||$22.81||$230,198.52|| |
|9/11/2015||Mark A Schlossberg||SVP||Sell||7,457||$43.30||$322,888.10|| |
|9/10/2015||Michael Nestor||Insider||Sell||5,000||$43.56||$217,800.00|| |
|8/31/2015||Michael Markbreiter||Director||Sell||28,000||$41.70||$1,167,600.00|| |
|8/27/2015||Mark A Schlossberg||SVP||Sell||4,649||$43.41||$201,813.09|| |
|8/27/2015||Peter R Terreri||Director||Sell||4,833||$43.93||$212,313.69|| |
|8/26/2015||Michael Markbreiter||Director||Sell||19,399||$42.24||$819,413.76|| |
|6/6/2014||Larry Hsu||Director||Sell||100,000||$28.38||$2,838,000.00|| |
|5/27/2014||Peter R Terreri||Director||Sell||3,000||$28.00||$84,000.00|| |
|5/22/2014||Larry Hsu||Director||Sell||50,000||$27.22||$1,361,000.00|| |
|5/21/2014||Larry Hsu||Director||Sell||3,800||$26.53||$100,814.00|| |
|5/16/2014||Nigel Fleming||Director||Sell||1,900||$25.72||$48,868.00|| |
|5/12/2014||Nigel Fleming||Director||Sell||1,333||$26.58||$35,431.14|| |
|5/8/2014||Michael Markbreiter||Director||Sell||12,500||$26.44||$330,500.00|| |
|5/6/2014||Larry Hsu||Director||Sell||219,386||$26.28||$5,765,464.08|| |
|3/11/2014||Michael Markbreiter||Director||Sell||4,000||$27.54||$110,160.00|| |
|1/8/2014||Robert Burr||Director||Sell||1,500||$24.31||$36,465.00|| |
|11/13/2013||Robert Burr||Director||Sell||1,500||$22.98||$34,470.00|| |
|10/9/2013||Robert Burr||Director||Sell||1,500||$20.10||$30,150.00|| |
|9/11/2013||Robert Burr||Director||Sell||1,500||$20.87||$31,305.00|| |
|8/14/2013||Robert Burr||Director||Sell||1,500||$21.15||$31,725.00|| |
|7/10/2013||Robert L Burr||Director||Sell||1,500||$20.26||$30,390.00|| |
|6/12/2013||Robert L Burr||Director||Sell||1,500||$18.80||$28,200.00|| |
|5/8/2013||Robert L Burr||Director||Sell||1,500||$16.35||$24,525.00|| |
|5/1/2013||Peter R Terreri||Director||Sell||3,450||$17.39||$59,995.50|| |
|3/12/2013||Larry Hsu||CEO||Buy||7,000||$16.88||$118,160.00|| |
|3/12/2013||Mark A Schlossberg||SVP||Buy||1,000||$16.73||$16,730.00|| |
|2/13/2013||Robert L Burr||Director||Sell||1,500||$19.82||$29,730.00|| |
|11/14/2012||Robert L Burr||Director||Sell||1,500||$19.86||$29,790.00|| |
|8/20/2012||Nigel Fleming||Director||Sell||6,000||$23.99||$143,940.00|| |
Headline Trends for Impax Laboratories (NASDAQ:IPXL)
Latest Headlines for Impax Laboratories (NASDAQ:IPXL)
Loading headlines, please wait.
Impax Laboratories (IPXL) Chart for Sunday, October, 22, 2017